Its use resulted in a 95% decrease in the rate of tetanus. It is on the World Health Organizations List of Essential Medicines. Medical uses
Effectiveness
Following vaccination, 95% of people are protected from diphtheria, 80% to 85% from pertussis, and 100% from tetanus. Globally deaths from tetanus in newborns decreased from 787,000 in 1988 to 58,000 in 2010, and 34,000 deaths in 2015 (a 96% decrease from 1988).In the 1940s, before the vaccine, there were about 550 cases of tetanus per year in the United States, which has decreased to about 30 cases per year in the 2000s. Nearly all cases are among those who have never received a vaccine, or adults who have not stayed up to date on their 10-year booster shots. Pregnancy
Guidelines on prenatal care in the United States specify that women should receive a dose of the Tdap vaccine during each pregnancy, preferably between weeks 27 and 36, to allow antibody transfer to the fetus. All postpartum women who have not previously received the Tdap vaccine are recommended to get it prior to discharge after delivery. It is recommended for pregnant women who have never received the tetanus vaccine (i.e., neither DTP or DTaP, nor DT as a child or Td or TT as an adult) to receive a series of three Td vaccinations starting during pregnancy to ensure protection against maternal and neonatal tetanus.
Plasmacytosis is a condition in which there is an unusually large proportion of plasma cells in tissues, exudates, or blood. : 743   Plasmacytosis may be divided into two types—cutaneous and systemic—both of which have identical skin findings. : 743 
Patients with plasmacytosis have been predominantly found to have lung infections (pneumonia, tuberculosis, abscess) whereas multiple myeloma is rarely found. See also
Cutaneous B-cell lymphoma
Multiple myeloma
Plasmacytoma
Skin lesion

References


== External links ==